<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hematopoietic disorders such as <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) show a high frequency of methylation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes </plain></SENT>
<SENT sid="1" pm="."><plain>DNA methyltransferase (DNMT) inhibitors such as <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi> are used to target DNA methylation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>Combining these drugs with <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase (HDAC) inhibitors in vitro resulted in synergistic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene re-expression </plain></SENT>
<SENT sid="3" pm="."><plain>Several phase I trials have examined methylation, gene expression and DNA damage as markers of clinical response to DNMT and HDAC inhibitors, with conflicting results </plain></SENT>
<SENT sid="4" pm="."><plain>Trials are ongoing to investigate early methylation changes and DNA damage markers to understand the mechanisms of these drugs and as potential predictors of clinical response </plain></SENT>
</text></document>